Any Time- Excessive?- I'm as excited as you seem to be about our investment- I make the time to find out what I can and over the years I have been rewarded with some nice nuggets of info- did you see that 2007 paper I found from am obscure but national mtg where HALO presented their work w rhupH20 and Humira- increased biovalabilty over 50%. It went from 64% w/o rhu to 100% with it. When I find these things I feel like "Stout Cortez" seeing the Pacific for the first time.
Pentech is a very consistent presence on this board- he's always wrong= like a rock.
An important corollary to this work is that it allows Polymorpho Nucleocytes- PMNs- to penetrate tumor- as was shown on Analyst day preclinical slide #35 -see SEC exhibit Jan 7 2015- SO PMNs like Activated T cells carry CD44- the HA binding receptor- SO if PegpH20 can carry out the penetration of PMNs into Pancreatic tumor cells- it just might do the same for CAR-T , TIL, and TCR- all carry CD44.
Halozyme Therapeutics' Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
- Co-Injection of rHuPH20 with Humira Estimated to Increase the Maximal Steady State Subcutaneous Bioavailability from 64% to 100% -
SAN DIEGO, July 09, 2007 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. , a biopharmaceutical company developing and commercializing recombinant human enzymes, today announced that final results of the Enhanze(TM) Technology clinical trial demonstrating improved absorption and bioavailability of a representative commercially-available large protein molecule therapeutic (LPMT) were presented at the 34th Annual Meeting of the Controlled Release Society in Long Beach, California. Enhanze Technology is Halozyme's enzyme-based drug delivery platform based on recombinant human PH20 hyaluronidase (rHuPH20). The abstract describing this trial was rated by the Controlled Release Society as having notable high scientific quality and was designated for a podium presentation, which included a recently completed modeled population pharmacokinetic (PK) analysis used to estimate the effect of steady state co-administration of rHuPH20 with the LPMT.
AMGN files 2 Petitions vs ABBV for Humira Biosimilar AP501-why won't they just Buyout HALO since it is well known that rhupH20 increases Humira bioavailbty by 56% (see 2007 paper presented by HALO at National meeting) - will work on biosimilars too.
It depends on how quickly they move- of course I think higher - big corporations move slowly and 202 may be halted on efficacy prior- will quickly send pps over 40 itself.
I don't want it either but the writing is on the wall -AMGN also has a CAR-T partnership with KITE - including solid tumors-how are they planning to make that happen? Kite doesn't even have switches-Pegph20 may be the answer.
PH-20 has been shown to aid penetration of oncolytic virus through the tumor cell membrane- right now T-VEC only works for Malignant Melanoma into which the virus is injected. In order to treat internal organs, Amgen will need to break down-yes-the tumor cells membranes-enter HALO with PegpH20 along with new (ex AMGN) CFO and (ex AMGN) CEO and Director K Falberg - ex AMGN CFO. Bid Coming.
Hey it's "Citizen" Pentech raising his failed argument yet again -yeah Baxter is so afraid of tigers that they are reporting better than expected uptake and conversion of HyQvia and are planning to expand it's indications-And as I wrote you before- with no response from you-I am making SO much money on my HALO long position-choosing to double down against all of the inane and just wrong positions you have taken here-you are a joke with a failed "Citizen Petition".
No I'm away since the 6th w limited internet access-as I stated on twitter before I left-guess you can take credit-btw-you're welcome to share my find of 2007 Halozyme presentation showing increase in Humira Bioavailability from 64% to 100% (amazing huh?) due to the addition of rhuph20. After all- we longs are all in this together.
Might have had a little to do with a tweet I posted this AM showing HALO did a study with Humira +rhupH20 in 2007- increased bioavailabilty by 56% from 64% to 100%- presented at a national mtg- so Enhanze will probably be used for Humira patent extension unless Amgen- which has 2 Humira biosimilars in the works- Buys HALO.
Yes good point, ethics will dictate treatment of controls.